Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck

Acta Oto-Laryngologica

Volumn 120, Issue 1, 2000, Pages 105-111

  Riedel, Frank ^a   Götte, Karl ^a   Schwalb, Joachim ^a   Schäfer, Carsten ^a   Hörmann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; Head and neck cancer; p53; Vascular endothelial growth factor

Indexed keywords

PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION FUNCTION; FEMALE; FROZEN SECTION; GENE CONTROL; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0033948951     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480060203334     Document Type: Article

References (29)

1. 1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
2. 2. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1991; 84: 1875-87.
3. 3. Kuehn R, Rojas W, Riedel F, Bergler W, Hörmann K. Tumour angiogenesis in head and neck squamous cell carcinoma. Br J Cancer 1998; 77: Suppl 1: 27.
4. 4. Folkman J, Klagsbrun M. Angiogenetic Factors. Science 1987; 235: 442-7.
5. 5. Dvorak HF, Brown LF, Detmar M, Dvorak HM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-39.
6. 6. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-37.
7. 7. Leung DW, Cachianes G, Kuang W, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenetic mitogen. Science 1989; 246: 1306-9.
8. 8. Zhang HT, Craft P, Scott PA, Ziehe M, Weich HA, Harris AL, et al. Enhancement of Tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Nat Cancer Inst 1995; 87: 213-9.
9. 9. Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, et al. Expression of p53 and vascular endothelial growth factor associated with tumour angiogenesis and prognosis in gastric cancer. Oncology 1998; 55: 594-9.
10. 10. Burian M, Quint Ch, Neuchrist C. Angiogenic factors in laryngeal carcinomas: Do the have prognostic relevance? Acta Otolaryngol (Stockh) 1999; 119: 289-92.
11. 11. Eisma RJ, Spiro JD, Kreutzer DL. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 1997; 174: 513-7.
12. 12. Salven P, Heikkilä P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Modern Pathol 1997; 10: 1128-33.
13. 13. Riedel F, Götte K, Schwalb J, Wirtz H, Bergler W, Hörmann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. European Archives of Oto-Rhino-Laryngology (in press).
14. 14. Levine AJ. The tumour suppressor genes. Ann Rev Biochem 1992; 62: 327-36.
15. 15. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentates protein kinase C induction of vascular endothelial growth factor expression in primary oesophageal squamous cell carcinoma. Oncogene 1994; 9: 963-9.
16. 16. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-5.
17. 17. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary oesophageal squamous cell carcinoma. Cancer 1997; 79: 206-13.
18. 18. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: co-ordinate induction of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-9.
19. 19. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998; 77: 1704-9.
20. 20. Xu L, Chen YT, Huvos AG. Overexpression of p53 protein in squamous cell carcinoma of the head and neck without apparent gene mutation. Diag Mol Pathol 1994; 3: 83-92.
21. 21. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-9.
22. 22. Kusama K, Okutsu S, Takeda A, Himiya T, Kojima A, Kidokoro Y, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996; 178: 415-21.
23. 23. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 712-7.
24. 24. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-34.
25. 25. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52: 79-98.
26. 26. Augustin HG. Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 1998; 19: 216-22.
27. 27. Martiny-Baron G, Marme D. VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol 1995; 6: 675-80.
28. 28. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
29. 29. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumour growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factorial. Cancer Res 1995; 55: 5296-301.